{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T05:29:13Z","timestamp":1786598953322,"version":"build-2736575974"},"reference-count":41,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Surgical Oncology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The publication of SARC028 in late 2017 revolutionized soft tissue sarcoma (STS) treatment by demonstrating promising response to anti\u2010PD1 immunotherapy in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS). Data on immunotherapy efficacy and outcomes in larger cohorts and with longer follow\u2010up remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>31\u2009672 cases of UPS, DDLPS, alveolar soft part sarcoma, and myxofibrosarcoma were extracted from the NCDB. Factors associated with the use of immunotherapy were evaluated using logistic regression, and survival analysis was performed with Kaplan\u2010Meier curves and Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients diagnosed with STS after 2017 were 3.67 times more likely to receive immunotherapy. Immunotherapy was associated with an approximately 20% reduction in mortality in stage IV STS, which was driven by cases of UPS. This survival benefit was observed in male, but not female, patients. There was no survival benefit in stage III STS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These data are consistent with a survival benefit with immunotherapy in stage IV STS, predominantly in UPS, supporting the findings of SARC028. Benefit in stage III STS was not observed, limiting concordance with later trials like SARC032. Further prospective data on long\u2010term outcomes and immunotherapy efficacy according to histology and sex are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jso.70371","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T05:12:51Z","timestamp":1786597971000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy in the Treatment of Soft Tissue Sarcoma Since SARC028: An NCDB Analysis"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8629-6267","authenticated-orcid":false,"given":"Galileo S.","family":"Dumont","sequence":"first","affiliation":[{"name":"University of Colorado School of Medicine Aurora Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna L.","family":"Gratny","sequence":"additional","affiliation":[{"name":"University of Colorado School of Medicine Aurora Colorado USA"},{"name":"Department of Orthopedic Surgery University of Colorado School of Medicine Aurora Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2709-7338","authenticated-orcid":false,"given":"Carson","family":"Keeter","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery University of Colorado School of Medicine Aurora Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5080-497X","authenticated-orcid":false,"given":"Breelyn A.","family":"Wilky","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Medical Oncology University of Colorado School of Medicine Aurora Colorado USA"},{"name":"University of Colorado Cancer Center Aurora Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9267-519X","authenticated-orcid":false,"given":"Ryan","family":"Lanning","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center Aurora Colorado USA"},{"name":"Department of Radiation Oncology University of Colorado School of Medicine Aurora Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan J.","family":"Donaldson","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery University of Colorado School of Medicine Aurora Colorado USA"},{"name":"University of Colorado Cancer Center Aurora Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3127-4912","authenticated-orcid":false,"given":"Steven W.","family":"Thorpe","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery University of Colorado School of Medicine Aurora Colorado USA"},{"name":"University of Colorado Cancer Center Aurora Colorado USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35906","article-title":"Twenty\u2010Five Years Without Progress: The Enduring Challenge of Soft Tissue Sarcomas","volume":"131","author":"Hardy N. J.","year":"2025","journal-title":"Cancer"},{"key":"e_1_2_11_3_1","doi-asserted-by":"crossref","first-page":"9104","DOI":"10.1245\/s10434-025-18223-7","article-title":"ASO Practice Guidelines Series: Soft Tissue Sarcoma of the Extremities and Superficial Trunk","volume":"32","author":"Callegaro D.","year":"2025","journal-title":"Annals of Surgical Oncology"},{"key":"e_1_2_11_4_1","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S1470-2045(20)30325-9","article-title":"Pathological Response in Children and Adults With Large Unresected Intermediate\u2010Grade or High\u2010Grade Soft Tissue Sarcoma Receiving Preoperative Chemoradiotherapy With or Without Pazopanib (ARST1321): A Multicentre, Randomised, Open\u2010Label, Phase 2 Trial","volume":"21","author":"Weiss A. R.","year":"2020","journal-title":"Lancet Oncology"},{"key":"e_1_2_11_5_1","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1470-2045(12)70346-7","article-title":"Adjuvant Chemotherapy With Doxorubicin, Ifosfamide, and Lenograstim for Resected Soft\u2010Tissue Sarcoma (EORTC 62931): A Multicentre Randomised Controlled Trial","volume":"13","author":"Woll P. J.","year":"2012","journal-title":"Lancet Oncology"},{"key":"e_1_2_11_6_1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/cncr.23592","article-title":"A Systematic Meta\u2010Analysis of Randomized Controlled Trials of Adjuvant Chemotherapy for Localized Resectable Soft\u2010Tissue Sarcoma","volume":"113","author":"Pervaiz N.","year":"2008","journal-title":"Cancer"},{"key":"e_1_2_11_7_1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/cncr.33895","article-title":"Neoadjuvant Chemotherapy in High\u2010Risk Soft Tissue Sarcomas: A Sarculator\u2010Based Risk Stratification Analysis of the ISG\u2010STS 1001 Randomized Trial","volume":"128","author":"Pasquali S.","year":"2022","journal-title":"Cancer"},{"key":"e_1_2_11_8_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210671","article-title":"A Meta\u2010Analysis of Randomized Controlled Trials That Compare Standard Doxorubicin With Other First\u2010Line Chemotherapies for Advanced\/Metastatic Soft Tissue Sarcomas","volume":"14","author":"Tanaka K.","year":"2019","journal-title":"PLoS One"},{"key":"e_1_2_11_9_1","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2020.1707","article-title":"Effect of Doxorubicin Plus Olaratumab Vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial","volume":"323","author":"Tap W. D.","year":"2020","journal-title":"Journal of the American Medical Association"},{"key":"e_1_2_11_10_1","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab Alone in Advanced Melanoma (Checkmate 067): 4\u2010Year Outcomes of a Multicentre, Randomised, Phase 3 Trial","volume":"19","author":"Hodi F. S.","year":"2018","journal-title":"Lancet Oncology"},{"key":"e_1_2_11_11_1","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood.2022019386","article-title":"Five\u2010Year Follow\u2010Up of KEYNOTE\u2010087: Pembrolizumab Monotherapy for Relapsed\/Refractory Classical Hodgkin Lymphoma","volume":"142","author":"Armand P.","year":"2023","journal-title":"Blood"},{"key":"e_1_2_11_12_1","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1002\/cncr.33033","article-title":"Nivolumab Versus Everolimus in Patients With Advanced Renal Cell Carcinoma: Updated Results With Long\u2010Term Follow\u2010Up of the Randomized, Open\u2010Label, Phase 3 Checkmate 025 Trial","volume":"126","author":"Motzer R. J.","year":"2020","journal-title":"Cancer"},{"key":"e_1_2_11_13_1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated Analysis of KEYNOTE\u2010024: Pembrolizumab Versus Platinum\u2010Based Chemotherapy for Advanced Non\u2013Small\u2010Cell Lung Cancer With PD\u2010L1 Tumor Proportion Score of 50% or Greater","volume":"37","author":"Reck M.","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_11_14_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102115","article-title":"Sarcomas: Immune Biomarker Expression and Checkpoint Inhibitor Trials","volume":"91","author":"Zhu M. M. T.","year":"2020","journal-title":"Cancer Treatment Reviews"},{"key":"e_1_2_11_15_1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/CCO.0000000000001149","article-title":"Which Sarcoma Requires PD1\/PDL1 Inhibitors, and What Should Be the Best Scheme? Present Status and Next Steps","volume":"37","author":"Martin\u2010Broto J.","year":"2025","journal-title":"Current Opinion in Oncology"},{"key":"e_1_2_11_16_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082870","article-title":"Tumor Infiltrating PD1\u2010Positive Lymphocytes and the Expression of PD\u2010L1 Predict Poor Prognosis of Soft Tissue Sarcomas","volume":"8","author":"Kim J. R.","year":"2013","journal-title":"PLoS One"},{"key":"e_1_2_11_17_1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.humpath.2014.11.001","article-title":"Prevalence of Tumor\u2010Infiltrating Lymphocytes and PD\u2010L1 Expression in the Soft Tissue Sarcoma Microenvironment","volume":"46","author":"D'Angelo S. P.","year":"2015","journal-title":"Human Pathology"},{"key":"e_1_2_11_18_1","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in Advanced Soft\u2010Tissue Sarcoma and Bone Sarcoma (SARC028): A Multicentre, Two\u2010Cohort, Single\u2010Arm, Open\u2010Label, Phase 2 Trial","volume":"18","author":"Tawbi H. A.","year":"2017","journal-title":"Lancet Oncology"},{"key":"e_1_2_11_19_1","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/s41591-022-01821-3","article-title":"Pembrolizumab in Soft\u2010Tissue Sarcomas With Tertiary Lymphoid Structures: A Phase 2 PEMBROSARC Trial Cohort","volume":"28","author":"Italiano A.","year":"2022","journal-title":"Nature Medicine"},{"key":"e_1_2_11_20_1","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(24)01812-9","article-title":"Safety and Efficacy of Pembrolizumab, Radiation Therapy, and Surgery Versus Radiation Therapy and Surgery for Stage III Soft Tissue Sarcoma of the Extremity (SU2C\u2010SARC032): An Open\u2010Label, Randomised Clinical Trial","volume":"404","author":"Mowery Y. M.","year":"2024","journal-title":"Lancet"},{"key":"e_1_2_11_21_1","unstructured":"National Comprehensive Cancer Network Soft Tissue Sarcoma 2.2026. Accessed February 18 2026 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/sarcoma.pdf."},{"key":"e_1_2_11_22_1","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S1470-2045(23)00282-6","article-title":"Pembrolizumab in Patients With Rare and Ultra\u2010Rare Sarcomas (AcS\u00e9 Pembrolizumab): Analysis of a Subgroup From a Non\u2010Randomised, Open\u2010Label, Phase 2, Basket Trial","volume":"24","author":"Blay J.\u2010Y.","year":"2023","journal-title":"Lancet Oncology"},{"key":"e_1_2_11_23_1","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2303383","article-title":"Atezolizumab for Advanced Alveolar Soft Part Sarcoma","volume":"389","author":"Chen A. P.","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_11_24_1","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1470-2045(19)30153-6","article-title":"Axitinib Plus Pembrolizumab in Patients With Advanced Sarcomas Including Alveolar Soft\u2010Part Sarcoma: A Single\u2010Centre, Single\u2010Arm, Phase 2 Trial","volume":"20","author":"Wilky B. A.","year":"2019","journal-title":"Lancet Oncology"},{"key":"e_1_2_11_25_1","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1470-2045(22)00392-8","article-title":"Durvalumab Plus Tremelimumab in Advanced or Metastatic Soft Tissue and Bone Sarcomas: A Single\u2010Centre Phase 2 Trial","volume":"23","author":"Somaiah N.","year":"2022","journal-title":"Lancet Oncology"},{"key":"e_1_2_11_26_1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab With or Without Ipilimumab Treatment for Metastatic Sarcoma (Alliance A091401): Two Open\u2010Label, Non\u2010Comparative, Randomised, Phase 2 Trials","volume":"19","author":"D'Angelo S. P.","year":"2018","journal-title":"Lancet Oncology"},{"key":"e_1_2_11_27_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114070","article-title":"Efficacy of Immune Checkpoint Inhibitors in the Treatment of Soft Tissue Sarcoma: A Systematic Review and Meta\u2010Analysis of Clinical Trials","volume":"148","author":"Cao Y.","year":"2025","journal-title":"International Immunopharmacology"},{"key":"e_1_2_11_28_1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaoncol.2022.6296","article-title":"Adoption of Innovative Therapies Across Oncology Practices\u2014Evidence from Immunotherapy","volume":"9","author":"Carroll C. E.","year":"2023","journal-title":"JAMA Oncology"},{"key":"e_1_2_11_29_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjsurg.2024.115794","article-title":"Trends in the Use of Immunotherapy to Treat Soft Tissue Sarcoma","volume":"236","author":"Iwai Y.","year":"2024","journal-title":"American Journal of Surgery"},{"key":"e_1_2_11_30_1","unstructured":"Participant User Files. ACS accessed January 31 2026 https:\/\/www.facs.org\/quality-programs\/cancer-programs\/national-cancer-database\/puf\/."},{"key":"e_1_2_11_31_1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-020-00891-5","article-title":"PD1\/PD\u2010L1 Targeting in Advanced Soft\u2010Tissue Sarcomas: A Pooled Analysis of Phase II Trials","volume":"13","author":"Italiano A.","year":"2020","journal-title":"Journal of Hematology & Oncology"},{"key":"e_1_2_11_32_1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s43018-024-00726-z","article-title":"A Randomized, Non\u2010Comparative Phase 2 Study of Neoadjuvant Immune\u2010Checkpoint Blockade in Retroperitoneal Dedifferentiated Liposarcoma and Extremity\/Truncal Undifferentiated Pleomorphic Sarcoma","volume":"5","author":"Roland C. L.","year":"2024","journal-title":"Nature Cancer"},{"key":"e_1_2_11_33_1","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025262","article-title":"Remarkable Response to Anti\u2010PD1 Immunotherapy in Refractory Metastatic High\u2010Grade Myxofibrosarcoma Patient: A Case Report","volume":"100","author":"Luo Y.","year":"2021","journal-title":"Medicine"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.725484"},{"key":"e_1_2_11_35_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108661","article-title":"Disparities in Adherence to Guideline\u2010Concordant Care and Receipt of Immunotherapy for Non\u2010Small Cell Lung Cancer in the United States","volume":"206","author":"Nykaza I.","year":"2025","journal-title":"Lung Cancer"},{"key":"e_1_2_11_36_1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.15656","article-title":"Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US","volume":"3","author":"Moyers J. T.","year":"2020","journal-title":"JAMA Network Open"},{"key":"e_1_2_11_37_1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10549-025-07725-3","article-title":"Clinical, Sociodemographic, and Facility\u2010Related Determinants of Immunotherapy Use in Metastatic Triple\u2010Negative Breast Cancer","volume":"212","author":"Ajjawi I.","year":"2025","journal-title":"Breast Cancer Research and Treatment"},{"key":"e_1_2_11_38_1","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/j.seminoncol.2022.09.004","article-title":"Under\u2010Representation of Women in Randomized Clinical Trials Testing Anticancer Immunotherapy May Undermine Female Patients Care. A Call to Action","volume":"49","author":"Pala L.","year":"2022","journal-title":"Seminars in Oncology"},{"key":"e_1_2_11_39_1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer Immunotherapy Efficacy and Patients' Sex: A Systematic Review and Meta\u2010Analysis","volume":"19","author":"Conforti F.","year":"2018","journal-title":"Lancet Oncology"},{"key":"e_1_2_11_40_1","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(18)30517-5","article-title":"Sex as a Predictor of Response to Cancer Immunotherapy","volume":"19","author":"Claggett B.","year":"2018","journal-title":"Lancet Oncology"},{"key":"e_1_2_11_41_1","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(18)30483-2","article-title":"Sex as a Predictor of Response to Cancer Immunotherapy","volume":"19","author":"McQuade J. L.","year":"2018","journal-title":"Lancet Oncology"},{"key":"e_1_2_11_42_1","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/s41586-025-09071-2","article-title":"Concurrent Loss of the Y Chromosome in Cancer and T Cells Impacts Outcome","volume":"642","author":"Chen X.","year":"2025","journal-title":"Nature"}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.70371","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jso.70371","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.70371","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T05:12:56Z","timestamp":1786597976000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.70371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":41,"alternative-id":["10.1002\/jso.70371"],"URL":"https:\/\/doi.org\/10.1002\/jso.70371","archive":["Portico"],"relation":{},"ISSN":["0022-4790","1096-9098"],"issn-type":[{"value":"0022-4790","type":"print"},{"value":"1096-9098","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"2026-03-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"jso.70371"}}